By Karen Roman
Biopharmaceutical company Medera Inc. said it completed patient enrollment for Cohort B of its clinical trial evaluating SRD-002 gene therapy for heart failure with preserved ejection fraction (HFpEF).
This milestone allows Medera to advance to Phase 2b of this trial and contributes to future treatment for this type of heart failure, which accounts to nearly half of the 64.3 million heart failure cases worldwide, the company stated.
“The very encouraging results to date support our confidence in advancing this first-in-human gene therapy approach for patients with HFpEF, a condition affecting approximately half of all heart failure patients worldwide with limited disease-modifying therapeutic options,” said Ronald Li, PhD, Medera’s CEO and founder.
READ MORE
A Look at Sheikh Ahmed Dalmook Al Maktoum’s Push to Link Capital with Community Outcomes
Register for our weekly newsletter HERE
Contact:
Click HERE to follow us on LinkedIn
